Radical Prostatectomy:
|
|
- Kathlyn Allison
- 5 years ago
- Views:
Transcription
1 Overtreatment and undertreatment Radical Prostatectomy: An Emerging Standard of Care for High Risk Prostate Cancer Matthew R. Cooperberg, MD,MPH UCSF Radiation Oncology Update San Francisco, CA April 2, 2011 Cooperberg et al. J Clin Oncol 2010; 28:1117 Natural history of high-risk disease Comparative Effectiveness Research Localized prostate cancer: IOM top 25 list for CER research No RCTs of surgery vs. radiation since 1982 Focus on prospectively-accrued registries with long-term followup to metastasis / mortality outcomes and robust risk adjustment Lu-Yao et al. JAMA 2009; 302:1202 1
2 CaPSURE: Patient characteristics Unadjusted outcomes RP N=5543 Age 61.5 ± Kattan 19.1 ± 14.7 EBRT N= ± ± 22.5 All-cause mortality: n=1466 Mean time to death 6.8 ± 4.0 years Cancer-specific mortality: n=261 PADT N=1484 Total N= ± ± ± ± 19.9 CAPRA 2.7 ± ± ± ± 2.0 Charlson 1.6 ± ± ± ± 1.3 Results: Cancer-specific mortality Adjusted all-cause mortality Predictors of Cancer-Specific Mortality Variable HR p 95% CI Age CAPRA 1.35 < RP Ref ERBT With By competing adjustment 1.96 risks by analysis: Kattan <0.001 rather than CAPRA: PADT EBRT HR ( ); ( ); PADT HR ( ) ( ) 3.26 < PADT:EBRT HR 1.7 ( ) Variable HR p 95% CI Age CAPRA 1.10 < Charlson 1.11 < RP Ref EBRT 1.52 < PADT 2.29 <
3 Predicted 10-year cancer-specific mortality Predicted 10-year cancer-specific mortality CAPRA RP EBRT PADT CAPRA ( ) 3.1 ( ) 5.0 ( ) CAPRA ( ) 4.2 ( ) 6.8 ( ) CAPRA ( ) 5.7 ( ) 9.1 ( ) CAPRA ( ) 7.6 ( ) 12.3 ( ) CAPRA ( ) 10.3 ( ) 16.4 ( ) CAPRA ( ) 13.8 ( ) 21.8 ( ) CAPRA ( ) 18.4 ( ) 28.5 ( ) CAPRA ( ) 24.3 ( ) 36.8 ( ) CAPRA ( ) 31.6 ( ) 46.6 ( ) CAPRA ( ) 40.5 ( ) 57.6 ( ) CAPRA ( ) 50.9 ( ) 69.0 ( ) Unmeasured confounding? Increase in Kattan score for RP patients HR for EBRT HR for PADT ( ) 3.22 ( ) ( ) 2.84 ( ) ( ) 2.50 ( ) ( ) 2.20 ( ) ( ) 1.94 ( ) ( ) 1.71 ( ) Example: an RP patient with GS 3+4, PSA 9, 30 ct2a would 1.03 have ( ) to have the same 1.51 actual ( ) risk as an EBRT patient with GS 3+3, PSA 4, ct1c ( ) 1.33 ( ) Strength of registries Not an RCT, but several strengths Identical followup regardless of primary treatment Independent (3rd party) data analysis Consistent definitions Real world outcomes 3
4 Caveats Variation / trends in EBRT technique/dose Variation in NADT/AADT use/duration (adjustment made no difference use tracks with risk) Insufficient mortality events for brachytherapy / cryotherapy / watchful waiting analyses Mortality estimates may overestimate risk for contemporary patients with better staging and treatment Results from MSKCC and Baylor 1318 RP and 1062 EBRT patients All EBRT was IMRT 81 Gy Short-course NADT in 56% Predictor for metastasis HR 95% CI P-value Age Year of treatment NCCN risk (high vs low/int) <0.001 Surgery vs. EBRT Zelefsky et al. J Clin Oncol 2010; 28:1508 Results from MSKCC and Baylor Results from MSKCC and Baylor 81 to 86Gy of EBRT may be insufficient Favor combined brachy + IMRT or surgery + EBRT Need for a surgical arm in future trials in high-risk disease Zelefsky et al. J Clin Oncol 2010; 28:1508 Zelefsky et al. J Clin Oncol 2010; 28:1508 4
5 Results from Washington U 4656 localized CaP patients 3652 RP (16% ACM) 1004 EBRT (31% ACM) Results from Cleveland Clinic 4222 men with low-intermediate risk disease tx ed RP, EBRT, brachy Control for age, PSA, Gleason score, BMI, stage, comorbidities 23 cancer-specific deaths (92 CAD deaths) Duan et al. AUA 2008 Ciezki et al. ASTRO 2009 Results from CCF / Wash U What about QOL? 10,472 men (6493 RP, 2260 EBRT, 1719 brachy) RT brachy + EBRT + NADT Lower-risk cohort overall than MSKCC or CaPSURE Cox and Fine & Gray analyses with age, race, risk, and comorbidity-based propensity score adjustment HR for ACM: 1.6 (95% CI ) and 1.7 (95% CI ), respectively, for EBRT and brachy relative to RP HR for CSM: 1.6 (95% CI ) and 1.1 (95% CI ) for EBRT and brachy relative to RP And don t forget about costs! Stephenson et al. AUA 2010 Wu et al. J Urol 2008; 180:2415 5
6 Conclusions Multiple studies in a variety of contexts with mature followup and robust risk-adjustment have shown a clear survival benefit for RP over EBRT (including IMRT). Magnitude of differences cannot be explained by variation in technique or ADT duration. Data re: brachy are less clear. RCTs between modalities in high-risk disease are needed Treatment for high-risk disease often must be multimodal, and should include surgery with greater frequency 6
Localized prostate cancer
Prostate Cancer 2014 Localized prostate cancer Progress toward personalized care Matthew R. Cooperberg, MD,MPH Departments of Urology and Epidemiology & Biostatistics UCSF Mini Medical School July 22,
More informationHigh Risk Localized Prostate Cancer Treatment Should Start with RT
High Risk Localized Prostate Cancer Treatment Should Start with RT Jason A. Efstathiou, M.D., D.Phil. Assistant Professor of Radiation Oncology Massachusetts General Hospital Harvard Medical School 10
More informationDetection & Risk Stratification for Early Stage Prostate Cancer
Detection & Risk Stratification for Early Stage Prostate Cancer Andrew J. Stephenson, MD, FRCSC, FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Risk Stratification:
More informationComparative Risk-Adjusted Mortality Outcomes After Primary Surgery, Radiotherapy, or Androgen-Deprivation Therapy for Localized Prostate Cancer
Comparative Risk-Adjusted Mortality Outcomes After Primary Surgery, Radiotherapy, or Androgen-Deprivation Therapy for Localized Prostate Cancer Matthew R. Cooperberg, MD, MPH 1 ; Andrew J. Vickers, PhD
More informationExternal Beam Radiation Therapy for Low/Intermediate Risk Prostate Cancer
External Beam Therapy for Low/Intermediate Risk Prostate Cancer Jeff Michalski, M.D. The Carlos A. Perez Distinguished Professor of Department of and Siteman Cancer Center Learning Objectives Understand
More informationDebate: Whole pelvic RT for high risk prostate cancer??
Debate: Whole pelvic RT for high risk prostate cancer?? WPRT well, at least it ll get the job done.or will it? Andrew K. Lee, MD, MPH Associate Professor Department of Radiation Oncology Using T-stage,
More informationPre-test. Prostate Cancer The Good News: Prostate Cancer Screening 2012: Putting the PSA Controversy to Rest
Pre-test Matthew R. Cooperberg, MD, MPH UCSF 40 th Annual Advances in Internal Medicine Prostate Cancer Screening 2012: Putting the PSA Controversy to Rest 1. I do not offer routine PSA screening, and
More informationPatterns in the Treatment of Intermediate and High Risk Localized Prostate Cancer
Patterns in the Treatment of Intermediate and High Risk Localized Prostate Cancer Jonathan E. Heinlen, M.D. Stephenson Oklahoma Cancer Center University of Oklahoma Health Sciences Center Disclosures I
More informationUnderstanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD
Understanding the risk of recurrence after primary treatment for prostate cancer Aditya Bagrodia, MD Aditya.bagrodia@utsouthwestern.edu 423-967-5848 Outline and objectives Prostate cancer demographics
More information3/22/2014. Goals of this Presentation: in 15 min & 5 min Q & A. Radiotherapy for. Localized Prostate Cancer: What is New in 2014?
3/22/ Goals of this Presentation: in 15 min & 5 min Q & A 1. Potency Preservation. a. Dosimetric considerations Radiotherapy for b. Drugs 2. Update on duration of short term ADT Mack III, MD Professor
More informationNIH Public Access Author Manuscript Cancer. Author manuscript; available in PMC 2011 November 15.
NIH Public Access Author Manuscript Published in final edited form as: Cancer. 2010 November 15; 116(22): 5226 5234. doi:10.1002/cncr.25456. Comparative risk-adjusted mortality outcomes following primary
More informationPaul F. Schellhammer, M.D. Eastern Virginia Medical School Urology of Virginia Norfolk, Virginia
Paul F. Schellhammer, M.D. Eastern Virginia Medical School Urology of Virginia Norfolk, Virginia Virginia - Chesapeake Bay Landfall: Virginia Beach, April 29 th, 1607 PSA Failure after Radical Prostatectomy
More informationThe Role of Adjuvant vs Salvage Radiation Therapy after Prostatectomy. Dr. Matt Andrews Supervisor: Dr. David Bowes
The Role of Adjuvant vs Salvage Radiation Therapy after Prostatectomy Dr. Matt Andrews Supervisor: Dr. David Bowes Objectives Discuss the evidence for adjuvant radiotherapy (ART) EORTC, SWOG, ARO Current
More informationThe Linked SEER-Medicare Data and Cancer Effectiveness Research
The Linked SEER-Medicare Data and Cancer Effectiveness Research Arnold L. Potosky, PhD Professor of Oncology Director of Health Services Research Georgetown University Medical Center Lombardi Comprehensive
More information2/14/09. Why Discuss this topic? Managing Local Recurrences after Radiation Failure. PROSTATE CANCER Second Treatment
Why Discuss this topic? Mack Roach III, MD Professor and Chair Radiation Oncology UCSF Managing Local Recurrences after Radiation Failure 1. ~15 to 75% of CaP pts recur after definitive RT. 2. Heterogeneous
More informationOverview of Radiotherapy for Clinically Localized Prostate Cancer
Session 16A Invited lectures: Prostate - H&N. Overview of Radiotherapy for Clinically Localized Prostate Cancer Mack Roach III, MD Department of Radiation Oncology UCSF Helen Diller Family Comprehensive
More informationTreatment of localized prostate cancer in elderly patients
Editorial Treatment of localized prostate cancer in elderly patients Mohammed Haseebuddin, Marc C. Smaldone Department of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA Correspondence
More informationTreatment Failure After Primary and Salvage Therapy for Prostate Cancer
307 Treatment Failure After Primary and Salvage Therapy for Prostate Cancer Likelihood, Patterns of Care, and Outcomes Piyush K. Agarwal, MD 1 Natalia Sadetsky, MD, MPH 2 Badrinath R. Konety, MD, MBA 2
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #104 (NQF 0390): Prostate Cancer: Combination Androgen Deprivation Therapy for High Risk or Very High Risk Prostate Cancer National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS
More informationErectile Dysfunction (ED) after Radiotherapy (RT) for Prostate Cancer. William M. Mendenhall, MD
Erectile Dysfunction (ED) after Radiotherapy (RT) for Prostate Cancer William M. Mendenhall, MD Meta-Analysis of Probability of Maintaining Erectile Function after Treatment of Localized Cancer Treatment
More informationDoes RT favor RP in long term Quality of Life? Juanita Crook MD FRCPC Professor of Radiation Oncology University of British Columbia
Does RT favor RP in long term Quality of Life? Juanita Crook MD FRCPC Professor of Radiation Oncology University of British Columbia Disclosures Advisory Board/honoraria: Varian Advisory Board: Breast
More informationClinical Case Conference
Clinical Case Conference Intermediate-risk prostate cancer 08/06/2014 Long Pham Clinical Case 64 yo man was found to have elevated PSA of 8.65. TRUS-biopies were negative. Surveillance PSA was 7.2 in 3
More informationModern Dose Fractionation and Treatment Techniques for Definitive Prostate RT
Modern Dose Fractionation and Treatment Techniques for Definitive Prostate RT Daniel J Bourgeois, III MD, MPH Board Certified Radiation Oncologist Southeast Louisiana Radiation Oncology Group (SLROG) Disclosures
More information2015 myresearch Science Internship Program: Applied Medicine. Civic Education Office of Government and Community Relations
2015 myresearch Science Internship Program: Applied Medicine Civic Education Office of Government and Community Relations Harguneet Singh Science Internship Program: Applied Medicine Comparisons of Outcomes
More informationProstate Cancer Genomics When To Treat and With What? Ashley E. Ross, M.D., Ph.D. Texas Urology Specialists August 2017
Prostate Cancer Genomics When To Treat and With What? Ashley E. Ross, M.D., Ph.D. Texas Urology Specialists August 2017 Relevant Disclosures Advisory role, ownership interest, previous unrestricted grant
More informationProstate Cancer: 2010 Guidelines Update
Prostate Cancer: 2010 Guidelines Update James L. Mohler, MD Chair, NCCN Prostate Cancer Panel Associate Director for Translational Research, Professor and Chair, Department of Urology, Roswell Park Cancer
More informationWhen radical prostatectomy is not enough: The evolving role of postoperative
When radical prostatectomy is not enough: The evolving role of postoperative radiation therapy Dr Tom Pickles Clinical Associate Professor, UBC. Chair, Provincial Genito-Urinary Tumour Group BC Cancer
More informationUCSF UC San Francisco Previously Published Works
UCSF UC San Francisco Previously Published Works Title Patterns of practice in the United States: insights from CaPSURE on prostate cancer management. Permalink https://escholarship.org/uc/item/24j7405c
More informationAdam Raben M.D. Helen F Graham Cancer Center
Adam Raben M.D. Helen F Graham Cancer Center Is the biopsy sample representative of the extent of the disease in your patient with clinically low-risk prostate cancer? BIOPSY RP registry (n=8095) 3+3=6
More informationPSA is rising: What to do? After curative intended radiotherapy: More local options?
Klinik und Poliklinik für Urologie und Kinderurologie Direktor: Prof. Dr. H. Riedmiller PSA is rising: What to do? After curative intended radiotherapy: More local options? Klinische und molekulare Charakterisierung
More information1259
Survival Among Men With Clinically Localized Prostate Cancer Treated With Radical Prostatectomy or Radiation Therapy in the Prostate Specific Antigen Era Adam S. Kibel,* Jay P. Ciezki, Eric A. Klein, Chandana
More informationGenomics and Genetic Testing. Copyright 2017 Myriad Genetics, Inc., all rights reserved.
Genomics and Genetic Testing Copyright 2017 Myriad Genetics, Inc., all rights reserved. www.myriad.com Why is genetic testing important to you? Impact on immediate treatment decisions Identify risks for
More informationRadical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease
Radical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease Disclosures I do not have anything to disclose Sexual function causes moderate to severe distress 2 years after
More informationEffective Health Care Program
Comparative Effectiveness Review Number 146 Effective Health Care Program Therapies for Clinically Localized Prostate Cancer: Update of a 2008 Systematic Review Executive Summary Background Prostate cancer
More informationSalvage HDR Brachytherapy. Amit Bahl Consultant Clinical Oncologist The Bristol Cancer Institute, UK
Salvage HDR Brachytherapy Amit Bahl Consultant Clinical Oncologist The Bristol Cancer Institute, UK Disclosures Still No financial disclosures! Limited personal experience of HDR Brachy as salvage option
More informationUC San Francisco UC San Francisco Previously Published Works
UC San Francisco UC San Francisco Previously Published Works Title Positive surgical margins in radical prostatectomy patients do not predict long-term oncological outcomes: Results from the Shared Equal
More informationPROVIDING TREATMENT INFORMATION FOR PROSTATE CANCER PATIENTS
PROVIDING TREATMENT INFORMATION FOR PROSTATE CANCER PATIENTS For patients with localized disease on biopsy* For patients with adverse pathology after prostatectomy Contact the GenomeDx Customer Support
More informationD. Jeffrey Demanes M.D. FACRO, FACR, FASTRO Director UCLA Brachytherapy combined HDR + EBRT 574 HDR monotherapy Total Patients
Salvage Prostate Brachytherapy D. Jeffrey Demanes M.D. FACRO, FACR, FASTRO Director UCLA Brachytherapy 1996-2013 1515 combined HDR + EBRT 574 HDR monotherapy 36 Salvage 2125 Total Patients No Disclosure
More informationVALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE
Session 3 Advanced prostate cancer VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE 1 PSA is a serine protease and the physiological role is believed to be liquefying the seminal fluid PSA
More informationStrategies of Radiotherapy for Intermediate- to High-Risk Prostate Cancer
Strategies of Radiotherapy for Intermediate- to High-Risk Prostate Cancer Daisaku Hirano, MD Department of Urology Higashi- matsuyama Municipal Hospital, Higashi- matsuyama- city, Saitama- prefecture,
More informationFocal Therapy is a Fool s Paradise : The whole prostate must be treated!
Focal Therapy is a Fool s Paradise : The whole prostate must be treated! Ofer Yossepowitch, MD Head, Department of Urology Tel Aviv Sourasky Medical Center Preaching against focal therapy in a focal therapy
More informationConsensus and Controversies in Cancer of Prostate BASIS FOR FURHTER STUDIES. Luis A. Linares MD FACRO Medical Director
BASIS FOR FURHTER STUDIES Main controversies In prostate Cancer: 1-Screening 2-Management Observation Surgery Standard Laparoscopic Robotic Radiation: (no discussion on Cryosurgery-RF etc.) Standard SBRT
More informationHeterogeneity in high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation therapy
Cagney et al. BMC Urology (2017) 17:60 DOI 10.1186/s12894-017-0250-2 RESEARCH ARTICLE Heterogeneity in high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation therapy
More informationTiming of Androgen Deprivation: The Modern Debate Must be conducted in the following Contexts: 1. Clinical States Model
Timing and Type of Androgen Deprivation Charles J. Ryan MD Associate Professor of Clinical Medicine UCSF Comprehensive Cancer Center Timing of Androgen Deprivation: The Modern Debate Must be conducted
More informationDate Modified: March 31, Clinical Quality Measures for PQRS
Date Modified: March 31, 2015 2015 Clinical Quality s for PQRS # Domain Title Description Type Denominator Numerator Denominator Exclusions/Exceptions 1 Patient Safety Prostate Biopsy Antibiotic Process
More informationProstate Cancer: from Beginning to End
Prostate Cancer: from Beginning to End Matthew D. Katz, M.D. Assistant Professor Urologic Oncology Robotic and Laparoscopic Surgery University of Arkansas for Medical Sciences Winthrop P. Rockefeller Cancer
More informationCorrespondence should be addressed to Taha Numan Yıkılmaz;
Advances in Medicine Volume 2016, Article ID 8639041, 5 pages http://dx.doi.org/10.1155/2016/8639041 Research Article External Validation of the Cancer of the Prostate Risk Assessment Postsurgical Score
More informationBest Papers. F. Fusco
Best Papers UROLOGY F. Fusco Best papers - 2015 RP/RT Oncological outcomes RP/RT IN ct3 Utilization trends RP/RT Complications Evolving role of elnd /Salvage LND This cohort reflects the current clinical
More informationPrior-Cancer Diagnosis in Men with Nonmetastatic Prostate Cancer and the Risk of Prostate-Cancer-Specific and All-Cause Mortality
Prior-Cancer Diagnosis in Men with Nonmetastatic Prostate Cancer and the Risk of Prostate-Cancer-Specific and All-Cause Mortality The Harvard community has made this article openly available. Please share
More informationActive surveillance for low-risk Prostate Cancer Compared with Immediate Treatment: A Canadian cost evaluation
Active surveillance for low-risk Prostate Cancer Compared with Immediate Treatment: A Canadian cost evaluation Alice Dragomir, PhD Fabio Cury, MD Armen Aprikian, MD Introduction Clinical and economic burden
More informationHow to deal with patients who fail intracavitary treatment
How to deal with patients who fail intracavitary treatment A. Heidenreich Department of Urology Non-surgical therapy of PCA IMRT SEEDS IGRT HDR-BRACHY HIFU CRYO LDR - Brachytherapy Author Follow-up bned
More informationSalvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes
ORIGINAL RESEARCH Salvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes Michael J. Metcalfe, MD ; Patricia Troncoso, MD 2 ; Charles C. Guo,
More informationRisk Migration ( ct2c=high)
Risk Migration ( ctc=high) Prostate Cancer Over- Detection, but Selective Treatment Active Surveillance Peter R. Carroll, MD, MPH Department of Urology University of California, San Francisco February,
More informationACTIVE SURVEILLANCE FOR PROSTATE CANCER
ACTIVE SURVEILLANCE FOR PROSTATE CANCER Dr. Michael J Metcalfe PGY-2 Department of Urological Sciences April 25, 2012 CASE RM 65 year old active Caucasian male, married. PSA= 7.0 T2a Gleason 3+3=6 2/6
More informationOncologic Outcomes Of Definitive Treatments For Low- & Intermediate-Risk Prostate Cancer After A Period Of Active Surveillance
Accepted Manuscript Oncologic Outcomes Of Definitive Treatments For Low- & Intermediate-Risk Prostate Cancer After A Period Of Active Surveillance Michael J. Whalen, Jamie S. Pak, Danny Lascano, David
More informationValidation of the 2015 Prostate Cancer Grade Groups for Predicting Long-Term Oncologic Outcomes in a Shared Equal-Access Health System
Original Article Validation of the 2015 Prostate Cancer Grade Groups for Predicting Long-Term Oncologic Outcomes in a Shared Equal-Access Health System Ariel A. Schulman, MD 1 ; Lauren E. Howard, MS 2
More informationNCCN Guidelines for Prostate V Meeting on 06/28/18
Guideline Page and Request PROS-2 through PROS-11 and PROS-D (pages 3 and 4). External request from GenomeDx Biosciences Request the NCCN Prostate Cancer Guidelines Panel to review the data in support
More informationDepartment of Urology, Inje University Busan Paik Hospital, Inje University College of Medicine, Busan, Korea
www.kjurology.org http://dx.doi.org/10.4111/kju.2014.55.5.321 Original Article - Urological Oncology http://crossmark.crossref.org/dialog/?doi=10.4111/kju.2014.55.5.321&domain=pdf&date_stamp=2014-05-16
More informationProtocol. This trial protocol has been provided by the authors to give readers additional information about their work.
Protocol This trial protocol has been provided by the authors to give readers additional information about their work. Protocol for: Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation
More informationOriginal Article. Cancer September 15,
Gleason Pattern 5 Is the Strongest Pathologic Predictor of Recurrence, Metastasis, and Prostate Cancer-Specific Death in Patients Receiving Salvage Radiation Therapy Following Radical Prostatectomy William
More informationLong-term Survival of Extremely Advanced Prostate Cancer Patients Diagnosed with Prostate-specific Antigen over 500 ng/ml
Jpn J Clin Oncol 2014;44(12)1227 1232 doi:10.1093/jjco/hyu142 Advance Access Publication 19 September 2014 Long-term Survival of Extremely Advanced Prostate Cancer Patients Diagnosed with Prostate-specific
More informationAblatherm Integrated Imaging HIFU Treatment of Low Risk, Localized Prostate Cancer
Ablatherm Integrated Imaging HIFU Treatment of Low Risk, Localized Prostate Cancer P130003 Gastroenterology and Urology Devices Panel Meeting July 30, 2014 CI-1 Presenters Cary Robertson, MD Associate
More informationMolDX: Oncotype DX Genomic Prostate Score for Men with Favorable Intermediate Risk Prostate Cancer
MolDX: Oncotype DX Genomic Prostate Score for Men with Favorable Intermediate Risk Prostate Cancer Noridian Healthcare Solutions, LLC Please Note: This is a Proposed LCD. Proposed LCDs are works in progress
More informationPatterns and Correlates of Prostate Cancer Treatment in Older Men
CLINICAL RESEARCH STUDY Patterns and Correlates of Prostate Cancer Treatment in Older Men Calpurnyia B. Roberts, PhD, a,b Peter C. Albertsen, MD, c Yu-Hsuan Shao, PhD, d Dirk F. Moore, PhD, d,g Amit R.
More informationSRO Tutorial: Prostate Cancer Clinics
SRO Tutorial: Prostate Cancer Clinics May 7th, 2010 Daniel M. Aebersold Klinik und Poliklinik für Radio-Onkologie Universität Bern, Inselspital Is cure necessary in those in whom it may be possible, and
More informationAppreciating the Natural History of Prostate Cancer in 2005: The Art of Medicine
Appreciating the Natural History of Prostate Cancer in 2: The Art of Medicine Larry Goldenberg, MD, FRCSC, FACS The Prostate Centre at VGH, University of British Columbia, Vancouver, Canada Prostate Cancer:
More informationA Genomic Approach to Active Surveillance
A Genomic Approach to Active Surveillance Eric A. Klein, M.D. Chairman Glickman Urological and Kidney Institute Professor of Surgery Cleveland Clinic Lerner College of Medicine Cleveland Clinic Disclosures
More informationEmbracing Technology & Timing of Salvage Hormones
Embracing Technology & Timing of Salvage Hormones Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology Sunnybrook Health Sciences Centre University of Toronto Us Too, Brampton October
More informationMultiinstitutional Validation of the UCSF Cancer of the Prostate Risk Assessment for Prediction of Recurrence After Radical Prostatectomy
2384 Multiinstitutional Validation of the UCSF Cancer of the Prostate Risk Assessment for Prediction of Recurrence After Radical Prostatectomy Matthew R. Cooperberg, MD, MPH 1 Stephen J. Freedland, MD
More informationconcordance indices were calculated for the entire model and subsequently for each risk group.
; 2010 Urological Oncology ACCURACY OF KATTAN NOMOGRAM KORETS ET AL. BJUI Accuracy of the Kattan nomogram across prostate cancer risk-groups Ruslan Korets, Piruz Motamedinia, Olga Yeshchina, Manisha Desai
More informationand OCM were co-primary endpoints.
pissn 1598-2998, eissn 2005-9256 Original Article https://doi.org/10.4143/crt.2017.004 Open Access Cancer-Specific Mortality among Korean Men with Localized or Locally Advanced Prostate Cancer Treated
More information2018 ASTRO Refresher Course: Prostate Cancer. Timur Mitin, MD PhD Oregon Health and Science University
2018 ASTRO Refresher Course: Prostate Cancer Timur Mitin, MD PhD Oregon Health and Science University Disclosures UpToDate Chapter author, royalties Oregon Health and Science University Practicing Radiation
More informationIntroduction. Original Article
bs_bs_banner International Journal of Urology (2015) 22, 363 367 doi: 10.1111/iju.12704 Original Article Prostate-specific antigen level, stage or Gleason score: Which is best for predicting outcomes after
More informationEORTC radiation Oncology Group Intergroup collaboration with RTOG EORTC 1331-ROG; RTOG 0924
EORTC radiation Oncology Group Intergroup collaboration with RTOG EORTC 1331-ROG; RTOG 0924 Title of the Study Medical Condition Androgen deprivation therapy and high dose radiotherapy with or without
More informationCase Discussions: Prostate Cancer
Case Discussions: Prostate Cancer Andrew J. Stephenson, MD FRCSC FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Elevated PSA 1 54 yo, healthy male, family Hx of
More information2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY
Measure #104 (NQF 0390): Prostate Cancer: Adjuvant Hormonal Therapy for High Risk or Very High Risk Prostate Cancer National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL
More informationPROSTATE CANCER SURVEILLANCE
PROSTATE CANCER SURVEILLANCE ESMO Preceptorship on Prostate Cancer Singapore, 15-16 November 2017 Rosa Nadal National Cancer Institute, NIH Bethesda, USA DISCLOSURE No conflicts of interest to declare
More informationManagement of Prostate Cancer
Management of Prostate Cancer An ESMO Perspective Alan Horwich Conflicts of Interest Disclosure Alan Horwich I have no personal conflicts of interest relating to prostate cancer. European Incidence and
More informationPCA MORTALITY VS TREATMENTS
PCA MORTALITY VS TREATMENTS Terrence P McGarty White Paper No 145 July, 2017 In a recent NEJM paper the authors argue that there is no material difference between a prostatectomy and just "observation"
More informationThe Harvard community has made this article openly available. Please share how this access benefits you. Your story matters.
An Exploration of Risk Stratification for Active Surveillance and Androgen Deprivation Therapy Side Effects for Prostate Cancer Utilizing Data From the Surveillance, Epidemiology, and End Results Database
More informationCAPRA-S predicts outcome for adjuvant and salvage external beam radiotherapy after radical prostatectomy
Original research CAPRA-S predicts outcome for adjuvant and salvage external beam radiotherapy after radical prostatectomy Michel Zimmermann, MD; 1 Guila Delouya, MD, MSc; 1,2 Abdullah M. Alenizi, MD;
More informationUnderstanding the Performance of Active Surveillance Selection Criteria in Diverse Urology Practices
Understanding the Performance of Active Surveillance Selection Criteria in Diverse Urology Practices Scott R. Hawken,* Paul R. Womble,* Lindsey A. Herrel, Zaojun Ye, Susan M. Linsell, Patrick M. Hurley,
More informationUC San Francisco UC San Francisco Previously Published Works
UC San Francisco UC San Francisco Previously Published Works Title The quantitative Gleason score improves prostate cancer risk assessment Permalink https://escholarship.org/uc/item/9wq7g6k5 Journal Cancer,
More information3/6/2018 PROSTATE CANCER IN 2018 OBJECTIVE WHAT IS THE PROSTATE? WHAT DOES IT DO? Rahul Mehan, MD
PROSTATE CANCER IN 2018 Rahul Mehan, MD East Valley Urology Center 6116 E Arbor Ave, Bldg 2, Suite 108 Mesa, AZ 85206 rmehan@evucenter.com www.evucenter.com Snapchat: Dr.NoodleKing OBJECTIVE Offer interactive
More informationFactors Associated with Initial Treatment for Clinically Localized Prostate Cancer
Factors Associated with Initial Treatment for Clinically Localized Prostate Cancer Preliminary Results from the National Program of Cancer Registries Patterns of Care Study (PoC1) NAACCR Annual Meeting
More informationPROSTATE CANCER CLINICAL PRACTICE GUIDELINES: CLINICAL AND ECONOMIC OUTCOMES
PROSTATE CANCER CLINICAL PRACTICE GUIDELINES: CLINICAL AND ECONOMIC OUTCOMES By MICHAEL DENNIS TAYLOR A DISSERTATION PRESENTED TO THE GRADUATE SCHOOL OF THE UNIVERSITY OF FLORIDA IN PARTIAL FULFILLMENT
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Gene Expression Profiling and Protein Biomarkers for Prostate Cancer Management Page 1 of 52 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Gene Expression Profiling
More informationSalvage Radical Prostatectomy for Radiation-recurrent Prostate Cancer: A Multi-institutional Collaboration
EUROPEAN UROLOGY 60 (2011) 205 210 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Prostate Cancer Editorial by Markus Graefen on pp. 211 213 of this issue
More informationImpact of urologists ownership of radiation equipment in the treatment of prostate cancer
Prostate Cancer and Prostatic Diseases (2017) 00, 1 5 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved 1365-7852/17 www.nature.com/pcan ORIGINAL ARTICLE Impact of urologists
More informationMP Gene Expression Profiling and Protein Biomarkers for Prostate Cancer Management
Medical Policy MP 2.04.111 BCBSA Ref. Policy: 2.04.111 Last Review: 11/15/2018 Effective Date: 02/15/2019 Section: Medicine Related Policies 2.04.33 Genetic and Protein Biomarkers for the Diagnosis and
More informationDate Modified: May 29, Clinical Quality Measures for PQRS
Date Modified: May 29, 2014 Clinical Quality s for PQRS # Domain Type Denominator Numerator Denominator Exclusions/Exceptions Rationale QCDR-1 QCDR-2 Patient Safety 102 Efficiency and Cost Reduction QCDR-3
More informationConceptual basis for active surveillance
Conceptual basis for active surveillance 1. Screening results in overdiagnosis 2. Clinically insignificant disease can be identified 3. All treatments have significant side effects and cost. 4. Delayed
More informationRacial variation in receipt of quality radiation therapy for prostate cancer
https://doi.org/10.1007/s10552-018-1065-5 BRIEF REPORT Racial variation in receipt of quality for prostate cancer Daniel J. Lee 1 Zhiguo Zhao 2 Li Ching Huang 2 Tatsuki Koyoma 2 Matthew J. Resnick 1 David
More informationFuture Directions in Prostate Cancer: The Case for Protons. John J. Coen, MD Helen & Harry Gray Cancer Center
Future Directions in Prostate Cancer: The Case for Protons John J. Coen, MD Helen & Harry Gray Cancer Center November 14, 2012 Protons and prostate cancer Early proton experience at the MGH The case for
More informationEUROPEAN UROLOGY 60 (2011)
EUROPEAN UROLOGY 60 (2011) 920 930 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Prostate Cancer Editorial by Monique J. Roobol and Eveline A.M. Heijnsdijk
More informationPredictive Models. Michael W. Kattan, Ph.D. Department of Quantitative Health Sciences and Glickman Urologic and Kidney Institute
Predictive Models Michael W. Kattan, Ph.D. Department of Quantitative Health Sciences and Glickman Urologic and Kidney Institute Treatment for clinically localized prostate cancer Trade off: Substantial
More informationAndrogen Deprivation With or Without Radiation Therapy for Clinically Node-Positive Prostate Cancer
JNCI J Natl Cancer Inst (2015) 107(7): djv119 doi:10.1093/jnci/djv119 First published online May 9, 2015 Article Androgen Deprivation With or Without Radiation Therapy for Clinically Node-Positive Prostate
More informationProviding Treatment Information for Prostate Cancer Patients
Providing Treatment Information for Prostate Cancer Patients For all patients with localized disease on biopsy For all patients with adverse pathology after prostatectomy See what better looks like Contact
More informationPORT after RP. Adjuvant. Salvage
PORT after RP Adjuvant Or Salvage RT after RP 40-50% PSA relapse after RP in HR Definition: PSA should be undetectable within 6 weeks of RP Initial PSA is measured 6-12 weeks after RP AUA defines biochemical
More informationHow to select the right patient for the right treatment: What role does sexuality play in Pca treatment?
How to select the right patient for the right treatment: What role does sexuality play in Pca treatment? Andrea Salonia, MD, PhD, FECSM Università Vita-Salute San Raffaele Director, URI-Urological Research
More information